Cargando…

Fremanezumab for preventive treatment of migraine: Functional status on headache-free days

OBJECTIVE: To evaluate the effect of fremanezumab on the functional status on headache-free days in phase 2 episodic migraine (EM) and chronic migraine (CM) studies. METHODS: Functional status data were collected prospectively via the electronic headache diary on all headache-free days by patients a...

Descripción completa

Detalles Bibliográficos
Autores principales:	VanderPluym, Juliana, Dodick, David W., Lipton, Richard B., Ma, Yuju, Loupe, Pippa S., Bigal, Marcelo E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6161555/ https://www.ncbi.nlm.nih.gov/pubmed/30120138 http://dx.doi.org/10.1212/01.wnl.0000544321.19316.40

Ejemplares similares

Fremanezumab in the treatment of migraines: evidence to date
por: Robblee, Jennifer, et al.
Publicado: (2019)

TEV-48125 for the preventive treatment of chronic migraine: Efficacy at early time points
por: Bigal, Marcelo E., et al.
Publicado: (2016)

Ubrogepant in the Acute Management of Migraine: A Narrative Review
por: Chiang, Chia-Chun, et al.
Publicado: (2021)

Fremanezumab Improved Migraine and Headache Attributed to Glioblastoma
por: Kawamura, Shin, et al.
Publicado: (2022)

Profile of Lasmiditan in the Acute Treatment of Migraine in Adults: Design, Development, and Place in Therapy
por: Anderson, Christopher C, et al.
Publicado: (2023)

Fremanezumab for migraine
Publicado: (2020)

Effects of fremanezumab in patients with chronic migraine and comorbid depression: Subgroup analysis of the randomized HALO CM study
por: Lipton, Richard B., et al.
Publicado: (2021)

Fremanezumab for migraine prevention: more effective, less costly
Publicado: (2020)

One-Time Use of Galcanezumab or Fremanezumab for Migraine Prevention
por: Katsuki, Masahito, et al.
Publicado: (2023)

Long-term safety, tolerability, and efficacy of fremanezumab in migraine: A randomized study
por: Goadsby, Peter J., et al.
Publicado: (2020)

Reduction in the severity and duration of headache following fremanezumab treatment in patients with episodic and chronic migraine
por: Ashina, Messoud, et al.
Publicado: (2021)

Migraine and behavior in children: influence of maternal headache frequency
por: Arruda, Marco A., et al.
Publicado: (2012)

Effect of fremanezumab on quality of life and productivity in patients with chronic migraine
por: Lipton, Richard B., et al.
Publicado: (2020)

Fremanezumab and Non-High-Dose Galcanezumab for Comorbid Cluster Headache in Patients with Migraine: Three Cases
por: Kashiwagi, Kenta, et al.
Publicado: (2023)

An Evidence-Based Review of Fremanezumab for the Treatment of Migraine
por: Urits, Ivan, et al.
Publicado: (2020)

Review of Tolerability of Fremanezumab for Episodic and Chronic Migraine
por: Root, Shane, et al.
Publicado: (2023)

Overview on the prevalence and impact of migraine
por: Bigal, Marcelo E., et al.
Publicado: (2004)

Fremanezumab: a disease-specific option for the preventive treatment of migraine, including difficult-to-treat migraine
por: Friedman, Deborah I., et al.
Publicado: (2020)

Fremanezumab for Migraine Prevention in Japanese Elderly Aged Over 70 Years Old
por: Katsuki, Masahito, et al.
Publicado: (2023)

The Impact of OnabotulinumtoxinA vs. Placebo on Efficacy Outcomes in Headache Day Responder and Nonresponder Patients with Chronic Migraine
por: Silberstein, Stephen D., et al.
Publicado: (2020)

The differential diagnosis of chronic daily headaches: an algorithm-based approach
por: Bigal, Marcelo E., et al.
Publicado: (2007)

Fremanezumab for the Preventive Treatment of Migraine: Subgroup Analysis by Number of Prior Preventive Treatments with Inadequate Response
por: Pazdera, Ladislav, et al.
Publicado: (2021)

Effect of Headache-Free Days on Disability, Productivity, Quality of Life, and Costs Among Individuals with Migraine
por: Lipton, Richard B., et al.
Publicado: (2020)

Migraine headache is present in the aura phase – a prospective study
por: Hansen, JM, et al.
Publicado: (2013)

Evaluation of the Safety of Calcitonin Gene-Related Peptide Antagonists for Migraine Treatment Among Adults With Raynaud Phenomenon
por: Breen, Ilana D., et al.
Publicado: (2021)

The global burden of migraine
por: Lipton, Richard B., et al.
Publicado: (2003)

A Pharmacokinetic Bioequivalence Study of Fremanezumab Administered Subcutaneously Using an Autoinjector and a Prefilled Syringe
por: Cherniakov, Irina, et al.
Publicado: (2021)

Safety and Efficacy of Fremanezumab for the Prevention of Migraine: A Meta-Analysis From Randomized Controlled Trials
por: Gao, Bixi, et al.
Publicado: (2020)

Fremanezumab for Chronic Migraine Prevention in Japanese Patients: Subgroup Analysis from Two International Trials
por: Saigoh, Kazumasa, et al.
Publicado: (2023)

Fremanezumab for Episodic Migraine Prevention in Japanese Patients: Subgroup Analysis from Two International Trials
por: Saigoh, Kazumasa, et al.
Publicado: (2023)

Reversion From Chronic Migraine to Episodic Migraine in Patients Treated With Fremanezumab: Post Hoc Analysis From HALO CM Study
por: Lipton, Richard B., et al.
Publicado: (2020)

Burden of Illness Among People with Migraine and ≥ 4 Monthly Headache Days While Using Acute and/or Preventive Prescription Medications for Migraine
por: Buse, Dawn C., et al.
Publicado: (2020)

Population pharmacokinetic modelling and simulation of fremanezumab in healthy subjects and patients with migraine
por: Fiedler‐Kelly, Jill B., et al.
Publicado: (2019)

Comorbid and co-occurring conditions in migraine and associated risk of increasing headache pain intensity and headache frequency: results of the migraine in America symptoms and treatment (MAST) study
por: Buse, Dawn C., et al.
Publicado: (2020)

Real-world impact of fremanezumab on migraine symptoms and resource utilization in the United States
por: McAllister, Peter, et al.
Publicado: (2021)

Real-world evidence of fremanezumab for treating migraine in Japan: a retrospective study
por: Ohtani, Seiya, et al.
Publicado: (2023)

Real-world experience with monthly and quarterly dosing of fremanezumab for the treatment of patients with migraine in Japan
por: Suzuki, Shiho, et al.
Publicado: (2023)

Optimal treatment strategy of fremanezumab in migraine prevention: a systematic review with network meta-analysis of randomized clinical trials
por: Huang, I-Hsin, et al.
Publicado: (2020)

Migraine day frequency in migraine prevention: longitudinal modelling approaches
por: Di Tanna, Gian Luca, et al.
Publicado: (2019)

Real-world effectiveness after initiating fremanezumab treatment in US patients with episodic and chronic migraine or difficult-to-treat migraine
por: Driessen, Maurice T., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_f6e2k94aqmesqunctk6mc9snjr